Fosun Pharma subsidiary cuts Suzhou Angel Fund capital

Shanghai Fosun Pharmaceutical announced a capital reduction in Suzhou Angel Fund, with total subscribed capital decreasing from RMB176 million to RMB100 million.

Ningbo Fuying, a wholly-owned subsidiary of Fosun Pharma, will reduce its subscribed capital by RMB47.5 million while maintaining its 62.50% equity interest in the fund. The RMB76 million reduction will take effect July 15, 2025.